[Apolipoprotein A-I can be a new tool in the treatment of atherosclerosis].
Five weekly infusions of apolipoprotein A-IMilano/phospholipid complex decreased mean percent coronary atheroma volume as estimated with intravascular ultrasound. The mechanism of action may be through reverse cholesterol transport or through an anti-inflammatory effect. Treatment with high-dose atorvastatin during 18 months did not decrease percent coronary atheroma volume as measured with the same technique. Large-scale efficacy and safety studies will be necessary in order to establish apolipoprotein A-I as the next tool to fight coronary heart disease. The study is in line with the cholesterol hypothesis.
Olsson
Anders G
AG
Institutionen för medicin och vård, Hälsouniversitetet och EM-kliniken, Universitetssjukhuset i Linköping. andol@imv.liu.se
D016632:Apolipoprotein A-I / Q000008:administration & dosage*; D008076:Cholesterol, HDL / Q000097:blood; D003324:Coronary Artery Disease / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007262:Infusions, Intravenous
D016632:Apolipoprotein A-I; D008076:Cholesterol, HDL